Dongfeng Zeng, Yu Fang, Yue Fei, Rong Liang, Haige Ye, Yun Liang, Xiuhua Sun, Michael Wang, Huiqiang Huang, Lugui Qiu, Yuxuan Che, Panpan Liu, Yi Wang, Tao Pan, Yao Lv, Jintai Deng, Shuhua Yi, Yizi He, Ling Xiao, Huijuan Lv, Jiangfang Feng, Huilai Zhang, Hui Zhou, Dehui Zou, Qingqing Cai
Regimens based on Bruton's tyrosine kinase inhibitors (BTKi) have been increasingly used to treat mantle cell lymphoma (MCL). A real-world multicenter study was conducted to characterize treatment patterns and outcomes in patients with newly diagnosed MCL by Chinese Hematologist and Oncologist Innovation Cooperation of the Excellent (CHOICE). The final analysis included 1261 patients. Immunochemotherapy was the most common first-line treatment, including R-CHOP in 34%, cytarabine-containing regimens in 21% and BR in 3% of the patients...
May 19, 2023: International Journal of Cancer. Journal International du Cancer